Associations - PD-L1 inhibitor

EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	KN046 Sensitive: C3 – Early Trials J Immunother Cancer - 3 days (New C3) KN046 Sensitive : C3 J Immunother Cancer - 3d	KN046 Sensitive: C3 – Early Trials J Immunother Cancer - 3 days KN046 Sensitive : C3 J Immunother Cancer - 3 days - (New C3)
TMB-H	Non Small Cell Lung Cancer	TMB-H	Non Small Cell Lung Cancer	M7824 Sensitive: B - Late Trials ASCO 2023 - 1 week (New B) M7824 Sensitive : B ASCO 2023 - 1wk	M7824 Sensitive: B - Late Trials ASCO 2023 - 1 week M7824 Sensitive : B ASCO 2023 - 1 week - (New B)
PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 expression	Non Small Cell Lung Cancer	atezolizumab Sensitive: A1 - Approval ASCO 2023 - 1 week (New C3) atezolizumab Sensitive : A1 ASCO 2023 - 1wk	atezolizumab Sensitive: A1 - Approval ASCO 2023 - 1 week atezolizumab Sensitive : A1 ASCO 2023 - 1 week - (New C3)
PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 expression	Non Small Cell Lung Cancer	durvalumab Sensitive: A1 - Approval ASCO 2023 - 1 week (New C3) durvalumab Sensitive : A1 ASCO 2023 - 1wk	durvalumab Sensitive: A1 - Approval ASCO 2023 - 1 week durvalumab Sensitive : A1 ASCO 2023 - 1 week - (New C3)
PD-L1 overexpression	Non Small Cell Lung Cancer	PD-L1 overexpression	Non Small Cell Lung Cancer	atezolizumab Sensitive: A1 - Approval ASCO 2023 - 1 week (New C3) atezolizumab Sensitive : A1 ASCO 2023 - 1wk	atezolizumab Sensitive: A1 - Approval ASCO 2023 - 1 week atezolizumab Sensitive : A1 ASCO 2023 - 1 week - (New C3)
HER-2 positive	Solid Tumor	HER-2 positive	Solid Tumor	KN046 + KN026 Sensitive: C2 – Inclusion Criteria ASCO 2023 - 1 week (New C3) KN046 + KN026 Sensitive : C2 ASCO 2023 - 1wk	KN046 + KN026 Sensitive: C2 – Inclusion Criteria ASCO 2023 - 1 week KN046 + KN026 Sensitive : C2 ASCO 2023 - 1 week - (New C3)
PD-L1 expression	Gastric Adenocarcinoma	PD-L1 expression	Gastric Adenocarcinoma	envafolimab Sensitive: C2 – Inclusion Criteria ASCO 2023 - 1 week (New C3) envafolimab Sensitive : C2 ASCO 2023 - 1wk	envafolimab Sensitive: C2 – Inclusion Criteria ASCO 2023 - 1 week envafolimab Sensitive : C2 ASCO 2023 - 1 week - (New C3)
TMB-H	Non Small Cell Lung Cancer	TMB-H	Non Small Cell Lung Cancer	PD-L1 inhibitor Sensitive: C3 – Early Trials ASCO 2023 - 1 week (New C3) PD-L1 inhibitor Sensitive : C3 ASCO 2023 - 1wk	PD-L1 inhibitor Sensitive: C3 – Early Trials ASCO 2023 - 1 week PD-L1 inhibitor Sensitive : C3 ASCO 2023 - 1 week - (New C3)
PD-L1 overexpression	Non Small Cell Lung Cancer	PD-L1 overexpression	Non Small Cell Lung Cancer	PD-L1 inhibitor Sensitive: C3 – Early Trials ASCO 2023 - 1 week (New C3) PD-L1 inhibitor Sensitive : C3 ASCO 2023 - 1wk	PD-L1 inhibitor Sensitive: C3 – Early Trials ASCO 2023 - 1 week PD-L1 inhibitor Sensitive : C3 ASCO 2023 - 1 week - (New C3)
HER-2 negative	Gastric Adenocarcinoma	HER-2 negative	Gastric Adenocarcinoma	envafolimab Sensitive: C3 – Early Trials ASCO 2023 - 1 week (New C3) envafolimab Sensitive : C3 ASCO 2023 - 1wk	envafolimab Sensitive: C3 – Early Trials ASCO 2023 - 1 week envafolimab Sensitive : C3 ASCO 2023 - 1 week - (New C3)
SLFN11 expression	Small Cell Lung Cancer	SLFN11 expression	Small Cell Lung Cancer	atezolizumab + talazoparib Sensitive: C3 – Early Trials ASCO 2023 - 1 week (New C3) atezolizumab + talazoparib Sensitive : C3 ASCO 2023 - 1wk	atezolizumab + talazoparib Sensitive: C3 – Early Trials ASCO 2023 - 1 week atezolizumab + talazoparib Sensitive : C3 ASCO 2023 - 1 week - (New C3)
TMB-H	Colorectal Cancer	TMB-H	Colorectal Cancer	bevacizumab + atezolizumab Sensitive: C3 – Early Trials ASCO 2023 - 1 week (New C3) bevacizumab + atezolizumab Sensitive : C3 ASCO 2023 - 1wk	bevacizumab + atezolizumab Sensitive: C3 – Early Trials ASCO 2023 - 1 week bevacizumab + atezolizumab Sensitive : C3 ASCO 2023 - 1 week - (New C3)
DLL3 overexpression	Small Cell Lung Cancer	DLL3 overexpression	Small Cell Lung Cancer	PD-L1 inhibitor Resistant: C3 – Early Trials ASCO 2023 - 1 week (New C3) PD-L1 inhibitor Resistant : C3 ASCO 2023 - 1wk	PD-L1 inhibitor Resistant: C3 – Early Trials ASCO 2023 - 1 week PD-L1 inhibitor Resistant : C3 ASCO 2023 - 1 week - (New C3)
MSI-H/dMMR + TMB-H	Solid Tumor	MSI-H/dMMR + TMB-H	Solid Tumor	atezolizumab Sensitive: C3 – Early Trials ASCO 2023 - 1 week (New C3) atezolizumab Sensitive : C3 ASCO 2023 - 1wk	atezolizumab Sensitive: C3 – Early Trials ASCO 2023 - 1 week atezolizumab Sensitive : C3 ASCO 2023 - 1 week - (New C3)
STK11 deletion + TTF1 positive	Lung Non-Squamous Non-Small Cell Cancer	STK11 deletion + TTF1 positive	Lung Non-Squamous Non-Small Cell Cancer	atezolizumab Sensitive: C3 – Early Trials ASCO 2023 - 1 week (New C3) atezolizumab Sensitive : C3 ASCO 2023 - 1wk	atezolizumab Sensitive: C3 – Early Trials ASCO 2023 - 1 week atezolizumab Sensitive : C3 ASCO 2023 - 1 week - (New C3)
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	PM8002 Sensitive: C3 – Early Trials ASCO 2023 - 1 week (New C3) PM8002 Sensitive : C3 ASCO 2023 - 1wk	PM8002 Sensitive: C3 – Early Trials ASCO 2023 - 1 week PM8002 Sensitive : C3 ASCO 2023 - 1 week - (New C3)
TMB-H	Endometrial Cancer	TMB-H	Endometrial Cancer	durvalumab Sensitive: C3 – Early Trials ASCO 2023 - 1 week (New C3) durvalumab Sensitive : C3 ASCO 2023 - 1wk	durvalumab Sensitive: C3 – Early Trials ASCO 2023 - 1 week durvalumab Sensitive : C3 ASCO 2023 - 1 week - (New C3)
VEGFA elevation	Renal Cell Carcinoma	VEGFA elevation	Renal Cell Carcinoma	bevacizumab + atezolizumab Resistant: C3 – Early Trials ASCO 2023 - 1 week (New C3) bevacizumab + atezolizumab Resistant : C3 ASCO 2023 - 1wk	bevacizumab + atezolizumab Resistant: C3 – Early Trials ASCO 2023 - 1 week bevacizumab + atezolizumab Resistant : C3 ASCO 2023 - 1 week - (New C3)
MLH1 methylation + MSI-H/dMMR + TMB-H	Endometrial Cancer	MLH1 methylation + MSI-H/dMMR + TMB-H	Endometrial Cancer	durvalumab Sensitive: C3 – Early Trials ASCO 2023 - 1 week (New C3) durvalumab Sensitive : C3 ASCO 2023 - 1wk	durvalumab Sensitive: C3 – Early Trials ASCO 2023 - 1 week durvalumab Sensitive : C3 ASCO 2023 - 1 week - (New C3)
MLH1 methylation + MSI-H/dMMR	Endometrial Cancer	MLH1 methylation + MSI-H/dMMR	Endometrial Cancer	durvalumab Sensitive: C3 – Early Trials ASCO 2023 - 1 week (New C3) durvalumab Sensitive : C3 ASCO 2023 - 1wk	durvalumab Sensitive: C3 – Early Trials ASCO 2023 - 1 week durvalumab Sensitive : C3 ASCO 2023 - 1 week - (New C3)
PD-L1 overexpression	Bladder Cancer	PD-L1 overexpression	Bladder Cancer	atezolizumab Sensitive: C1 - Off-label Int J Radiat Oncol Biol Phys - 2 weeks (New C3) atezolizumab Sensitive : C1 Int J Radiat Oncol Biol Phys - 2wk	atezolizumab Sensitive: C1 - Off-label Int J Radiat Oncol Biol Phys - 2 weeks atezolizumab Sensitive : C1 Int J Radiat Oncol Biol Phys - 2 weeks - (New C3)
PD-L1 expression	Triple Negative Breast Cancer	PD-L1 expression	Triple Negative Breast Cancer	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	durvalumab Sensitive: A1 - Approval durvalumab Sensitive : A1	durvalumab Sensitive: A1 - Approval durvalumab Sensitive : A1
No biomarker	Small Cell Lung Cancer	No biomarker	Small Cell Lung Cancer	durvalumab Sensitive: A1 - Approval durvalumab Sensitive : A1	durvalumab Sensitive: A1 - Approval durvalumab Sensitive : A1
PD-L1 expression	Urothelial Cancer	PD-L1 expression	Urothelial Cancer	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1
No biomarker	Lung Non-Squamous Non-Small Cell Cancer	No biomarker	Lung Non-Squamous Non-Small Cell Cancer	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1
No biomarker	Small Cell Lung Cancer	No biomarker	Small Cell Lung Cancer	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1
No biomarker	Hepatocellular Cancer	No biomarker	Hepatocellular Cancer	bevacizumab + atezolizumab Sensitive: A1 - Approval bevacizumab + atezolizumab Sensitive : A1	bevacizumab + atezolizumab Sensitive: A1 - Approval bevacizumab + atezolizumab Sensitive : A1
No biomarker	Urothelial Cancer	No biomarker	Urothelial Cancer	avelumab Sensitive: A1 - Approval avelumab Sensitive : A1	avelumab Sensitive: A1 - Approval avelumab Sensitive : A1
BRAF V600	Melanoma	BRAF V600	Melanoma	atezolizumab + vemurafenib + cobimetinib Sensitive: A1 - Approval atezolizumab + vemurafenib + cobimetinib Sensitive : A1	atezolizumab + vemurafenib + cobimetinib Sensitive: A1 - Approval atezolizumab + vemurafenib + cobimetinib Sensitive : A1
PD-L1 expression	Renal Cell Carcinoma	PD-L1 expression	Renal Cell Carcinoma	avelumab + axitinib Sensitive: A1 - Approval avelumab + axitinib Sensitive : A1	avelumab + axitinib Sensitive: A1 - Approval avelumab + axitinib Sensitive : A1
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	bevacizumab + atezolizumab Sensitive: A1 - Approval bevacizumab + atezolizumab Sensitive : A1	bevacizumab + atezolizumab Sensitive: A1 - Approval bevacizumab + atezolizumab Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	avelumab + axitinib Sensitive: A1 - Approval avelumab + axitinib Sensitive : A1	avelumab + axitinib Sensitive: A1 - Approval avelumab + axitinib Sensitive : A1
No biomarker	Lung Non-Squamous Non-Small Cell Cancer	No biomarker	Lung Non-Squamous Non-Small Cell Cancer	bevacizumab + atezolizumab Sensitive: A1 - Approval bevacizumab + atezolizumab Sensitive : A1	bevacizumab + atezolizumab Sensitive: A1 - Approval bevacizumab + atezolizumab Sensitive : A1
ALK positive	Non Small Cell Lung Cancer	ALK positive	Non Small Cell Lung Cancer	bevacizumab + atezolizumab Sensitive: A1 - Approval bevacizumab + atezolizumab Sensitive : A1	bevacizumab + atezolizumab Sensitive: A1 - Approval bevacizumab + atezolizumab Sensitive : A1
No biomarker	Merkel Cell Carcinoma	No biomarker	Merkel Cell Carcinoma	avelumab Sensitive: A1 - Approval avelumab Sensitive : A1	avelumab Sensitive: A1 - Approval avelumab Sensitive : A1
ALK positive	Non Small Cell Lung Cancer	ALK positive	Non Small Cell Lung Cancer	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1
No biomarker	Urothelial Cancer	No biomarker	Urothelial Cancer	durvalumab Sensitive: A1 - Approval durvalumab Sensitive : A1	durvalumab Sensitive: A1 - Approval durvalumab Sensitive : A1
No biomarker	Urothelial Cancer	No biomarker	Urothelial Cancer	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	durvalumab + tremelimumab Sensitive: A1 - Approval durvalumab + tremelimumab Sensitive : A1	durvalumab + tremelimumab Sensitive: A1 - Approval durvalumab + tremelimumab Sensitive : A1
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	sugemalimab Sensitive: A1 - Approval sugemalimab Sensitive : A1	sugemalimab Sensitive: A1 - Approval sugemalimab Sensitive : A1
No biomarker	Biliary Tract Cancer	No biomarker	Biliary Tract Cancer	durvalumab Sensitive: A1 - Approval durvalumab Sensitive : A1	durvalumab Sensitive: A1 - Approval durvalumab Sensitive : A1
No biomarker	Hepatocellular Cancer	No biomarker	Hepatocellular Cancer	durvalumab Sensitive: A1 - Approval durvalumab Sensitive : A1	durvalumab Sensitive: A1 - Approval durvalumab Sensitive : A1
No biomarker	Hepatocellular Cancer	No biomarker	Hepatocellular Cancer	durvalumab + tremelimumab Sensitive: A1 - Approval durvalumab + tremelimumab Sensitive : A1	durvalumab + tremelimumab Sensitive: A1 - Approval durvalumab + tremelimumab Sensitive : A1
No biomarker	Soft Tissue Sarcoma	No biomarker	Soft Tissue Sarcoma	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1
PD-L1 overexpression	Non Small Cell Lung Cancer	PD-L1 overexpression	Non Small Cell Lung Cancer	durvalumab Sensitive: A2 - Guideline durvalumab Sensitive : A2	durvalumab Sensitive: A2 - Guideline durvalumab Sensitive : A2
BRAF V600	Cutaneous Melanoma	BRAF V600	Cutaneous Melanoma	atezolizumab + vemurafenib + cobimetinib Sensitive: A2 - Guideline atezolizumab + vemurafenib + cobimetinib Sensitive : A2	atezolizumab + vemurafenib + cobimetinib Sensitive: A2 - Guideline atezolizumab + vemurafenib + cobimetinib Sensitive : A2
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	atezolizumab Sensitive: A2 - Guideline atezolizumab Sensitive : A2	atezolizumab Sensitive: A2 - Guideline atezolizumab Sensitive : A2
PD-L1 expression	Bladder Cancer	PD-L1 expression	Bladder Cancer	atezolizumab Sensitive: A2 - Guideline atezolizumab Sensitive : A2	atezolizumab Sensitive: A2 - Guideline atezolizumab Sensitive : A2
PD-L1 expression	Lung Non-Squamous Non-Small Cell Cancer	PD-L1 expression	Lung Non-Squamous Non-Small Cell Cancer	atezolizumab Sensitive: A2 - Guideline atezolizumab Sensitive : A2	atezolizumab Sensitive: A2 - Guideline atezolizumab Sensitive : A2
No biomarker	Clear Cell Renal Cell Carcinoma	No biomarker	Clear Cell Renal Cell Carcinoma	avelumab + axitinib Sensitive: A2 - Guideline avelumab + axitinib Sensitive : A2	avelumab + axitinib Sensitive: A2 - Guideline avelumab + axitinib Sensitive : A2
PD-L1 overexpression	Non Small Cell Lung Cancer	PD-L1 overexpression	Non Small Cell Lung Cancer	bevacizumab + atezolizumab Sensitive: A2 - Guideline bevacizumab + atezolizumab Sensitive : A2	bevacizumab + atezolizumab Sensitive: A2 - Guideline bevacizumab + atezolizumab Sensitive : A2

PD-L1 inhibitor

PD-L1 inhibitor

Associations(676)

Associations
(676)